Preprint Communication Version 1 Preserved in Portico This version is not peer-reviewed

Acquired Intergenic ANK3-RET Fusion as a Pralsetinib-Responsive Mechanism of Resistance to Osimertinib in EGFR-Mutated NSCLC

Version 1 : Received: 31 October 2021 / Approved: 2 November 2021 / Online: 2 November 2021 (22:19:36 CET)

How to cite: Urbanska, E.M.; Sørensen, J.B.; Melchior, L.C.; Costa, J.C.; Santoni-Rugiu, E. Acquired Intergenic ANK3-RET Fusion as a Pralsetinib-Responsive Mechanism of Resistance to Osimertinib in EGFR-Mutated NSCLC. Preprints 2021, 2021110052 (doi: 10.20944/preprints202111.0052.v1). Urbanska, E.M.; Sørensen, J.B.; Melchior, L.C.; Costa, J.C.; Santoni-Rugiu, E. Acquired Intergenic ANK3-RET Fusion as a Pralsetinib-Responsive Mechanism of Resistance to Osimertinib in EGFR-Mutated NSCLC. Preprints 2021, 2021110052 (doi: 10.20944/preprints202111.0052.v1).

Abstract

The unavoidable progression of EGFR-mutated NSCLC on EGFR-TKIs forces us to discover solutions for further therapies. Herein, we discuss the necessity of accurate genomic mapping of progressive disease illustrated by a patient case. Tumor rebiopsies at progression are strongly needed to characterize acquired resistance to EGFR-TKI. The necessary data, however, may be reliably obtained only by deep targeted next generation sequencing (NGS) of both DNA and RNA. The reported case is a patient with EGFR-mutant NSCLC, who progressed during second line Osimertinib with subsequent targeted treatment determined by the detection of an acquired intergenic ANK3-RET-fusion with concomitant PTEN-mutation and MDM2-amplification. These three acquired gene alterations represent potential mechanisms of TKI-resistance, not previously reported on second line Osimertinib. Yet, while PTEN-mutations and MDM2-amplification are currently undruggable, the ANK3-RET fusion allowed further personalized treatment by combining continuation of Osimertinib with the RET-TKI Pralsetinib, which resulted in objective partial response, so far for 7 months, and significant clinical improvement. Hence, complementary DNA- and RNA-based targeted NGS may be of importance in clinical routine to better reveal the current molecular state of the disease and contribute to the identification of further targeted therapy strategies. Indeed, further cases with acquired RET-fusions, including ANK3-RET, should be investigated to fully determine the effectiveness of RET-TKI-Osimertinib combinations.

Keywords

RNA-based NGS; EGFR mutated NSCLC; acquired resistance; RET-fusion; rebiopsy

Subject

MEDICINE & PHARMACOLOGY, Oncology & Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.